Literature DB >> 2175324

IL-1 alpha induces expression of active transforming growth factor-beta in nonproliferating T cells via a post-transcriptional mechanism.

L A Bristol1, F W Ruscetti, D T Brody, S K Durum.   

Abstract

IL-1 is a co-stimulus for T cell proliferation along with TCR cross-linking agents or lectins. Here we demonstrate that IL-1 alpha, in the absence of a TCR stimulus, induces active TGF-beta production by non-proliferating T cells. Thus, in addition to being an incomplete signal, IL-1 alpha alone induced the production of a negative modulator for T cell proliferation. Interestingly, when Con A and IL-1 were combined, active TGF-beta was not detected in supernatants. Production of active TGF-beta protein by T cells in response to IL-1 alpha was established by 1) growth inhibition of the TGF-beta-responsive CCL 64 target cell, 2) neutralization of the activity in supernatants with an anti-TGF-beta mAb, and 3) competition of supernatants with [125I]TGF-beta binding to CCL 64 membranes. The mechanism of IL-1 alpha induction of TGF-beta was examined: IL-1 alpha did not increase TGF beta-1 message over constitutive levels, nor did it induce transcription of TGF-beta 2 message. A latent acid-activatable form of the protein was detected in nonproliferating murine T cells. We therefore suggest that IL-1 alpha regulates TGF-beta expression in T cells through translational and/or post-translational mechanisms. IL-1 regulation of active TGF-beta production by T cells may be a mechanism for controlling the proliferative response of T cells to a co-stimulus, and may be relevant in the pathophysiology of certain chronic inflammatory disease states.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175324

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.

Authors:  E Satoh; H Naganuma; A Sasaki; M Nagasaka; H Ogata; H Nukui
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

2.  Regulation of cytokine production by human Th0 cells following stimulation with peptide analogues: differential expression of TGF-beta in activation and anergy.

Authors:  D C Tsitoura; C M Gelder; D M Kemeny; J R Lamb
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

3.  The release of transforming growth factor-beta following haemorrhage: its role as a mediator of host immunosuppression.

Authors:  A Ayala; D R Meldrum; M M Perrin; I H Chaudry
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

4.  Splenic T-lymphocyte functions during early syphilitic infection are complex.

Authors:  T J Fitzgerald; M A Tomai
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Regulation of transforming growth factor-beta 1 gene expression by glucocorticoids in normal human T lymphocytes.

Authors:  O AyanlarBatuman; A P Ferrero; A Diaz; S A Jimenez
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

6.  Enhanced production of transforming growth factor-beta (TGF-beta) during autologous mixed lymphocyte reaction of systemic sclerosis patients.

Authors:  H Ota; S Kumagai; A Morinobu; H Yanagida; K Nakao
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

7.  Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.

Authors:  A Miller; O Lider; A B Roberts; M B Sporn; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 8.  Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure.

Authors:  S M Wahl
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

Review 9.  DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of Radioresistance.

Authors:  Lucia Centurione; Francesca B Aiello
Journal:  Front Oncol       Date:  2016-07-22       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.